Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicity
Improve efficiency, reduce late-stage failures, and align with regulatory standards by assessing the proarrhythmic liability of your compounds early. The potency data derived from high-fidelity platforms such as automated patch-clamp and the gold standard manual patch-clamp technique, is suitable for use in in silico action potential models. Our full cardiac ion channel panel includes: hERG (including a robust, dynamic hERG assay), KVLQT1/mink, hKV4.3/KChIP, hCaV1.2, hNaV1.5 (peak and late), hKIR2.1. Screening services against hHCN4 and hKV1.5, which play important roles in controlling human heart rate and atrial repolarisation, respectively, are also provided.
Learn more about our cardiac ion channel panel.
Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicity
The ability to achieve patch-clamp-equivalent data quality using VSD enhances predictive accuracy, reducing false negatives and late-stage failures, and supports safer drug development with improved preclinical-to-clinical translation.